You are here » Home » Companies » Company Overview » Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis Ltd.

BSE: 540701 Sector: Health care
NSE: DCAL ISIN Code: INE385W01011
BSE 00:00 | 17 Jan 229.85 1.15
(0.50%)
OPEN

230.40

HIGH

231.90

LOW

228.00

NSE 00:00 | 17 Jan 230.80 0.20
(0.09%)
OPEN

231.75

HIGH

233.20

LOW

227.90

OPEN 230.40
PREVIOUS CLOSE 228.70
VOLUME 7828
52-Week high 396.55
52-Week low 202.60
P/E 69.44
Mkt Cap.(Rs cr) 3,710
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 230.40
CLOSE 228.70
VOLUME 7828
52-Week high 396.55
52-Week low 202.60
P/E 69.44
Mkt Cap.(Rs cr) 3,710
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Dishman Carbogen Amcis Ltd. (DCAL) - Chairman Speech

Company chairman speech

Chairman & Managing Director’s Message

Dear Shareholders

It is my honour and privilege to interact with you as the Chairman of the Board. The_scal has been an exciting one for the Company. We took the opportunity to strengthen ourbusiness by reducing our operating expenses and capital investment while continuing todrive our efforts towards utilising our capacities in an optimal manner. We remain oncourse to meet our strategic targets and deliver sustainably. We are fully confident thatDishman will continue to succeed and thrive in the future.

Today we are a global and integrated CRAMS player with strong capabilities across thevalue chain – from process research and development to late-stage clinical andcommercial manufacturing. We are proud to have become the preferred outsourcing partneracross continents and countries and also to service customers from all the key advancedmarkets including US Europe and Asia. The global pharmaceutical and bio-pharmaceuticalCRAMS market has been growing year on year with an increasing emphasis on genericalternatives from developed countries. Global pharmaceutical companies are focusing onmarketing and discovery and are outsourcing drug development clinical trials andmanufacturing.

OUR KEY CAPABILITIES OF STRONG CHEMISTRY SKILLS LOW COST AND FLEXIBLE MANUFACTURINGPROCESSES ARE HELPING US ESTABLISH STRONG CUSTOMER RELATIONSHIPS AND SUSTAIN HIGHERPROFITABILITY.

We are leveraging our key capabilities of strong chemistry skills low cost andflexible manufacturing processes focused operations and our product portfolio. Thesefactors have helped Dishman establish strong customer relationships leading to scale-upin our CRAMS and API businesses and have helped sustain higher profitability and betterreturn ratios. These are also the factors that we capitalise on to differentiate ourselvesfrom other Indian CRAMS players.

Laying our Foundation for Long-Term Growth

At Dishman our focus continues to be on improving our margins with higher capacityutilisation and high margin revenues from the niche and highly potent compounds. We arealso focusing on improving our asset turnover and return ratios and improving ourliquidity to capture business opportunities for even stronger growth. We have been gainingthe flexibility to manufacture from either of the facilities thereby reducing dependenceon a single plant. This will also free up the capacity constraint at Carbogen Amcisallowing the site to focus on early phase chemical synthesis work. Going forward weremain on course to meet our strategic targets and deliver sustainably. We are confidentof the Dishman Group continuing to succeed and thrive in the future.

I take this opportunity to convey thanks to our Board Members for their constantguidance and support. We look forward to their support as we continue to create long-termvalue for our stakeholders.

On behalf of the Board we thank our the shareholders for believing in us theManagement of Dishman Carbogen Amcis and the employees for their loyalty andcontribution.

Janmejay R. Vyas

Chairman & Managing Director